| 14.63 -0.26 (-1.75%) | 12-08 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 18.52 | 1-year : | 21.63 |
| Resists | First : | 15.85 | Second : | 18.52 |
| Pivot price | 14.47  |
|||
| Supports | First : | 13.74 | Second : | 12.44 |
| MAs | MA(5) : | 14.65 |
MA(20) : | 14.38 |
| MA(100) : | 13.72 |
MA(250) : | 0 | |
| MACD | MACD : | 0.2 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 71.3 |
D(3) : | 68 |
| RSI | RSI(14): 53 |
|||
| 52-week | High : | 20.5 | Low : | 7.72 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ GHRS ] has closed below upper band by 41.5%. Bollinger Bands are 39% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 15.28 - 15.38 | 15.38 - 15.46 |
| Low: | 14.42 - 14.52 | 14.52 - 14.6 |
| Close: | 14.49 - 14.65 | 14.65 - 14.78 |
GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable 5-MeO-DMT product candidate that has completed two Phase 1 clinical trials and Phase 1/2 clinical trial in patients with TRD. The company also develops GH002, an injectable 5-MeO-DMT product candidate; and GH003, an intranasal 5-MeO-DMT product candidate, which are in preclinical development trials with a focus on psychiatric and neurological disorders. GH Research PLC was incorporated in 2018 and is based in Dublin, Ireland.
Sun, 07 Dec 2025
GH Research PLC (NASDAQ:GHRS) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Mon, 24 Nov 2025
GH Research to Present Promising Results on GH001 at ACNP 2026 - TipRanks
Mon, 10 Nov 2025
Wall Street Analysts Think GH Research (GHRS) Could Surge 130.59%: Read This Before Placing a Bet - Zacks Investment Research
Thu, 06 Nov 2025
GH Research Reports Third Quarter 2025 Financial Results and Provides Business Updates - GlobeNewswire
Mon, 13 Oct 2025
Depression-Focused GH Research Shares Could See Significant Upside: Analyst - Benzinga
Mon, 13 Oct 2025
Needham Initiates Coverage of GH Research (GHRS) with Buy Recommendation - Nasdaq
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 62 (M) |
| Shares Float | 23 (M) |
| Held by Insiders | 26.7 (%) |
| Held by Institutions | 71.9 (%) |
| Shares Short | 1,690 (K) |
| Shares Short P.Month | 1,730 (K) |
| EPS | -0.74 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.69 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -14.2 % |
| Return on Equity (ttm) | -17.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.92 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -42 (M) |
| Levered Free Cash Flow | -30 (M) |
| PE Ratio | -20.05 |
| PEG Ratio | 0 |
| Price to Book value | 3.11 |
| Price to Sales | 0 |
| Price to Cash Flow | -21.78 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|